Enumeral Biomedical Holdings Inc.
Taking checkpoint inhibition to the next level
This article was originally published in Start Up
Checkpoint inhibitors have caused a sensation in oncology in recent years, but biotech Enumeral Biomedical Holdings Inc. is setting its sights on the Achilles' heel of the new antibodies – the high failure rate – using a discovery platform that employs cells from human biopsies, rather than more commonly used rodent models.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
In an interview at the recent Biotech Showcase, CEO Arthur Tinkelenberg explains his company’s approach to developing the next generation of checkpoint inhibitors.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.